Let-7, an established tumor suppressor microRNA, plays a key role in lung tissue repair and the development of scarring, a ...

Nerandomilast slowed lung function decline in people with IPF and PPF after a year of treatment, according to data from two ...

If your journey with pulmonary fibrosis were a movie, what best describes the genre? Horror? Comedy? Drama? Reality? Wait, how about a Hallmark movie? When I was diagnosed with idiopathic pulmonary ...

I couldn’t decide whether to open my column this week with “I hate this disease” or “This disease simply isn’t fair.” It’s been one of those weeks when both statements are true. I hate this disease, ...

A Phase 2 clinical trial has begun recruiting that’s assessing the safety and efficacy of LTI-03, Rein Therapeutics’ inhaled therapy for idiopathic pulmonary fibrosis (IPF). RENEW (NCT06968845) is ...

GRI Bio has reached an interim enrollment goal for its Phase 2a clinical trial testing GRI-0621 — a therapy targeting natural killer T-cells (NKT cells) to treat idiopathic pulmonary fibrosis (IPF) — ...

A committee of the European Medicines Agency (EMA) is recommending orphan drug status — a designation that aims to speed therapy development in rare diseases — for tranilast, the active ingredient in ...

Leave no stone unturned. This is a basic tenet of any investigation, something I learned very early in my career as a special agent. It also seems to be a practice employed by my healthcare team, ...

Pulmonary fibrosis (PF) is a respiratory condition that causes the formation of scar tissue in the lungs. It is progressive disease and can take years to progress. Because of thickening lung tissue, ...